Time New York: Wed 13 Dec 21:12 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

Zacks

Concert Pharmaceuticals, Inc. CNCE was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $16.15–$22.93 in the past one-month time frame, witnessed a sharp increase on Friday.

Concert Pharmaceuticals has seen the Zacks Consensus Estimate for the current quarter being revised downward in the past one month, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

The company currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Concert Pharmaceuticals, Inc. Price and Consensus


A better ranked stock in the Zacks Medical – Drugs industry is Akebia Therapeutics, Inc. AKBA which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is CNCE going up? Or down? Predict to see what others think: Up or Down

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.